Cullinan Associates’s Edwards Lifesciences EW Stock Holding History

Cullinan Associates’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.01M	Hold	12,600	–	–	0.08%	121
2025 Q4	$1.07M	Hold	12,600	–	–	0.07%	127
2025 Q3	$980K	Hold	12,600	–	–	0.06%	133
2025 Q2	$985K	Hold	12,600	–	–	0.07%	128
2025 Q1	$913K	Hold	12,600	–	–	0.06%	131
2024 Q4	$933K	Sell	12,600 -1,311	-9%	-$91.8K	0.06%	137
2024 Q3	$973K	Hold	13,911	–	–	0.05%	143
2024 Q2	$1.28M	Hold	13,911	–	–	0.07%	132
2024 Q1	$1.33M	Buy	13,911 +1,100	+9%	+$92.4K	0.07%	136
2023 Q4	$977K	Hold	12,811	–	–	0.05%	145
2023 Q3	$888K	Hold	12,811	–	–	0.05%	149
2023 Q2	$1.21M	Hold	12,811	–	–	0.07%	147
2023 Q1	$1.06M	Hold	12,811	–	–	0.06%	155
2022 Q4	$956K	Hold	12,811	–	–	0.05%	163
2022 Q3	$1.06M	Hold	12,811	–	–	0.07%	140
2022 Q2	$1.22M	Buy	12,811 +6,300	+97%	+$652K	0.07%	132
2022 Q1	$766K	Hold	6,511	–	–	0.04%	157
2021 Q4	$844K	Hold	6,511	–	–	0.04%	149
2021 Q3	$737K	Hold	6,511	–	–	0.04%	158
2021 Q2	$674K	Buy	6,511 +1,311	+25%	+$124K	0.04%	153
2021 Q1	$435K	Hold	5,200	–	–	0.03%	166
2020 Q4	$474K	Buy	+5,200	New	+$431K	0.03%	148

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Cullinan Associates's EW Position: Q1 2026 in Review

Cullinan Associates held its Edwards Lifesciences (EW) position steady in Q1 2026 at 12,600 shares worth $1.01M. The position accounts for 0.08% of the portfolio, ranked #121.

Cullinan Associates first reported a position in EW in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.33M in Q1 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Cullinan Associates held 12,600 shares of Edwards Lifesciences worth $1.01M as of Q1 2026.
Cullinan Associates left its Edwards Lifesciences share count unchanged in Q1 2026.
Edwards Lifesciences made up 0.08% of Cullinan Associates's portfolio in Q1 2026, its #121 holding.
Cullinan Associates first reported a position in Edwards Lifesciences in Q4 2020 and has held it in 22 quarters since.
Cullinan Associates's Edwards Lifesciences position peaked at $1.33M in Q1 2024.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Cullinan Associates's 13F filing for Q1 2026, filed 1 May 2026.